As of June 2024 Novavax has a market cap of $2.21 Billion. This makes Novavax the world's 3956th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $2.21 B | 288.27% |
2023 | $0.57 B | -34.75% |
2022 | $0.87 B | -91.92% |
2021 | $10.81 B | 52.38% |
2020 | $7.09 B | 5413.03% |
2019 | $0.12 B | -81.8% |
2018 | $0.70 B | 51.97% |
2017 | $0.46 B | 36.2% |
2016 | $0.34 B | -84.91% |
2015 | $2.26 B | 59.93% |
2014 | $1.41 B | 32.57% |
2013 | $1.06 B | 282.07% |
2012 | $0.27 B | 93.02% |
2011 | $0.14 B | -46.31% |
2010 | $0.26 B | 1.17% |
2009 | $0.26 B | 104.01% |
2008 | $0.13 B | -36.63% |
2007 | $0.20 B | -18.57% |
2006 | $0.25 B | 20.22% |
2005 | $0.21 B | 63.42% |
2004 | $0.12 B | -38.1% |
2003 | $0.20 B | 220.84% |
2002 | $64.92 M | -80.23% |
2001 | $0.32 B |
On Jun 1st, 2024 the market cap of Novavax was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Novartis NVS | $210.42 B | 9,404.88% | ๐จ๐ญ Switzerland |
Pfizer PFE | $162.40 B | 7,235.71% | ๐บ๐ธ USA |
AstraZeneca AZN | $241.89 B | 10,826.41% | ๐ฌ๐ง UK |
GlaxoSmithKline GSK | $93.92 B | 4,142.46% | ๐ฌ๐ง UK |
Sarepta Therapeutics
SRPT | $12.27 B | 454.45% | ๐บ๐ธ USA |
Celldex Therapeutics CLDX | $2.19 B | -0.86% | ๐บ๐ธ USA |
Agenus
AGEN | $0.32 B | -85.12% | ๐บ๐ธ USA |
NanoViricides NNVC | $28.35 M | -98.72% | ๐บ๐ธ USA |
BioCryst Pharmaceuticals
BCRX | $1.33 B | -39.78% | ๐บ๐ธ USA |
Emergent BioSolutions
EBS | $0.29 B | -86.51% | ๐บ๐ธ USA |